GlaxoSmithKline is to sell off its famous bedtime malted milk drink Horlicks in the UK, and will also consider exiting a pharma business, its cephalosporins antibiotics franchise. This gloomy news ...

GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over $4 billion and potentially use the cash for Novartis' buy out deal. Bloomberg ...

In 2020, HUL purchased the Horlicks brand from GSK for Rs 3,045 crore. The deal did not involve any transfer of shares or corporate ownership, only the brand name. The tax department argues that ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK GSK0.69%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...